



Viyash: Business Update


Revenues



EBITDA¹



EBITDA¹ margin



PAT



Note: 1. Viyash EBITDA is adjusted for ESOP costs

- New products launches
- CDMO growth
- Product mix
- Network optimisation
- Backward and Forward integration


Revenues



EBITDA¹



EBITDA¹ margin



PAT



Note: 1. Viyash EBITDA is adjusted for ESOP costs

Financial performance

All values in ₹ Mn




Particulars	Q2 FY26	Q2 FY25	Grw YoY%	Q1 FY26	Grw QnQ %
Revenue from Operations	4,281	3,632	18%	3,527	21%
Material Consumption	(1,667)	(1,625)	3%	(1,480)	13%
Gross Margin	2,614	2,008	30%	2,047	28%
%	61.1%	55.3%		58.0%	
Employee Benefit Expenses	(561)	(598)	-6%	(581)	-3%
Operating Expenses	(875)	(798)	10%	(788)	11%
Exchange Gain/(Loss)	55	17		10	
EBITDA (Pre-ESOP)⁽¹⁾	1,233	629	96%	688	79%
%	28.8%	17.3%	11%	19.5%	
ESOP Cost	(14)	(189)	-93%	(16)	-14%
EBITDA	1,219	440	177%	672	81%
%	28.5%	12.1%		19.1%	
Exceptional Items ⁽¹⁾	-	(29)		-	
Other Income	10	61		23	
Finance Cost	(40)	(65)		(63)	
Depreciation & Amortisation	(191)	(174)		(164)	
Amortization of Acquisition Intangibles	(245)	(236)		(241)	
Earnings Before Tax	752	(2)		228	
Taxes	(219)	(80)		(35)	
Earnings After Tax	533	(82)		193	

H1 FY26	H1 FY25	Grw YoY	FY 25
7,808	7,032	11%	14,580
(3,147)	(3,204)	-2%	(6,608)
4,661	3,828	22%	7,971
59.7%	54.4%		54.7%
(1,142)	(1,192)	-4%	(2,471)
(1,663)	(1,454)	14%	(3,018)
66	26		65
1,921	1,209	59%	2,546
24.6%	17.2%		17.5%
(30)	(218)	-86%	(237)
1,891	991	91%	2,309
24.2%	14.1%		15.8%
-	(58)		(824)
33	88		182
(103)	(144)		(256)
(355)	(353)		(720)
(486)	(469)		(1,003)
980	54		(311)
(254)	(148)		146
726	(94)		(165)

- Healthy revenue growth. Q2FY26 revenue grew by 18% YoY. H1FY26 YoY growth of 11%
- Gross Margin improved to 61.1% in Q2FY26 from 54.7% in FY25 and 58% in Q1FY26
- EBITDA % improved to 28.8% in Q2 FY26 from 17.5 % in FY25 and 19.5% in Q1FY26
- Significant improvement in profit before tax, profit after tax.

Key updates from Q2 FY26



Facility Inspections

- ✓ **4** Regulatory Audits
- ✓ **56** Customer audits
- ✓ **1** US FDA EIR



Products Filed

- ✓ **9 Filings** – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1)
- ✓ **FDFs -Nil**



Regulatory Approvals

- ✓ **2 APIs:** (USDMF-1 ; EDQM-1)



Validations Completed

- ✓ **3 APIs**



Launches

- ✓ **2 FDFs** (US)
- ✓ **2 APIs**



R&D Pipeline

- ✓ **16+** Products

P&L – Snapshot

Particulars	Viyash	
	FY25	H1 FY26
Revenue from Operations	14,580	7,808
Material Consumption	(6,608)	(3,147)
Gross Margin	7,971	4,661
%	54.7%	59.7%
Operating Expenses	(5,490)	(2,799)
Operating Exchange Gain / (Loss)	65	59
EBITDA³	2,546	1,921
%	17.5%	24.6%
ESOP cost	(82)	(30)
Exceptional Items ¹	(979)	-
Ind AS 29 Adjustment	-	-
Exchange Gain / (Loss)	-	-
Other Income	182	33
Finance Cost	(256)	(103)
D&A	(720)	(355)
Amortization of Acquisition Intangibles	(1,003)	(486)
Profit Before Tax	(311)	980
Taxes	146	(254)
Profit After Tax	(165)	726
Adjusted PAT²	1,296	1083

1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and provision for contractual one-time bonus

2. PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax)

3. Adjusted for ESOP costs

New production block commissioned in record time



- New production block created in short time to improve capacity, productivity and cost of Sequent products.
- One large volume Sequent API validated & filing under progress